Proteoglycan-targeted antibodies as markers on non-Hodgkin lymphoma xenografts

L. Kópper, Agnes Bankfalvi, R. Mihalik, Tibor T. Glant, J. Tímár

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

A family of mono- and polyclonal antibodies raised against proteoglycans or their "subcomponents" served as novel markers to characterize the phenotypes of three non-Hodgkin lymphoma xenograft lines (HT 58 lymphoblastic, HT 117 centroblastic, HT 130 centrocytic) together with normal, human peripheral blood B lymphocytes. These xenografted NHL lines, maintained by serial transplantations on artificially immunosuppressed mice, expressed very similar B-cell-related antigens and differences on the cell surface (HT 58 > HT 117 > HT 130 > B cells) when they were exposed to monoclonal antibodies (mAb) to cartilage proteoglycans. Anti-proteoglycan antibodies used in this study recognize complex epitopes of core protein segment associated with carbohydrate, shared by human cartilage proteoglycans and certain lymphoma cells. The binding of these antibodies was independent of cell-cycle phase. The results suggest that the anti-proteoglycan mAbs could be used as new phenotypic markers to individualize non-Hodgkin lymphomas.

Original languageEnglish
Pages (from-to)137-142
Number of pages6
JournalCancer Immunology Immunotherapy
Volume32
Issue number2
DOIs
Publication statusPublished - Mar 1990

Fingerprint

Proteoglycans
Heterografts
Non-Hodgkin's Lymphoma
Antibodies
B-Lymphocytes
Cartilage
Monoclonal Antibodies
Epitopes
Anti-Idiotypic Antibodies
Lymphoma
Cell Cycle
Transplantation
Carbohydrates
Phenotype
Antigens
Proteins

ASJC Scopus subject areas

  • Oncology
  • Immunology
  • Cancer Research

Cite this

Proteoglycan-targeted antibodies as markers on non-Hodgkin lymphoma xenografts. / Kópper, L.; Bankfalvi, Agnes; Mihalik, R.; Glant, Tibor T.; Tímár, J.

In: Cancer Immunology Immunotherapy, Vol. 32, No. 2, 03.1990, p. 137-142.

Research output: Contribution to journalArticle

@article{f87ec684adc249de8365ebeb95930f0e,
title = "Proteoglycan-targeted antibodies as markers on non-Hodgkin lymphoma xenografts",
abstract = "A family of mono- and polyclonal antibodies raised against proteoglycans or their {"}subcomponents{"} served as novel markers to characterize the phenotypes of three non-Hodgkin lymphoma xenograft lines (HT 58 lymphoblastic, HT 117 centroblastic, HT 130 centrocytic) together with normal, human peripheral blood B lymphocytes. These xenografted NHL lines, maintained by serial transplantations on artificially immunosuppressed mice, expressed very similar B-cell-related antigens and differences on the cell surface (HT 58 > HT 117 > HT 130 > B cells) when they were exposed to monoclonal antibodies (mAb) to cartilage proteoglycans. Anti-proteoglycan antibodies used in this study recognize complex epitopes of core protein segment associated with carbohydrate, shared by human cartilage proteoglycans and certain lymphoma cells. The binding of these antibodies was independent of cell-cycle phase. The results suggest that the anti-proteoglycan mAbs could be used as new phenotypic markers to individualize non-Hodgkin lymphomas.",
author = "L. K{\'o}pper and Agnes Bankfalvi and R. Mihalik and Glant, {Tibor T.} and J. T{\'i}m{\'a}r",
year = "1990",
month = "3",
doi = "10.1007/BF01754211",
language = "English",
volume = "32",
pages = "137--142",
journal = "Cancer Immunology, Immunotherapy",
issn = "0340-7004",
publisher = "Springer Science and Business Media Deutschland GmbH",
number = "2",

}

TY - JOUR

T1 - Proteoglycan-targeted antibodies as markers on non-Hodgkin lymphoma xenografts

AU - Kópper, L.

AU - Bankfalvi, Agnes

AU - Mihalik, R.

AU - Glant, Tibor T.

AU - Tímár, J.

PY - 1990/3

Y1 - 1990/3

N2 - A family of mono- and polyclonal antibodies raised against proteoglycans or their "subcomponents" served as novel markers to characterize the phenotypes of three non-Hodgkin lymphoma xenograft lines (HT 58 lymphoblastic, HT 117 centroblastic, HT 130 centrocytic) together with normal, human peripheral blood B lymphocytes. These xenografted NHL lines, maintained by serial transplantations on artificially immunosuppressed mice, expressed very similar B-cell-related antigens and differences on the cell surface (HT 58 > HT 117 > HT 130 > B cells) when they were exposed to monoclonal antibodies (mAb) to cartilage proteoglycans. Anti-proteoglycan antibodies used in this study recognize complex epitopes of core protein segment associated with carbohydrate, shared by human cartilage proteoglycans and certain lymphoma cells. The binding of these antibodies was independent of cell-cycle phase. The results suggest that the anti-proteoglycan mAbs could be used as new phenotypic markers to individualize non-Hodgkin lymphomas.

AB - A family of mono- and polyclonal antibodies raised against proteoglycans or their "subcomponents" served as novel markers to characterize the phenotypes of three non-Hodgkin lymphoma xenograft lines (HT 58 lymphoblastic, HT 117 centroblastic, HT 130 centrocytic) together with normal, human peripheral blood B lymphocytes. These xenografted NHL lines, maintained by serial transplantations on artificially immunosuppressed mice, expressed very similar B-cell-related antigens and differences on the cell surface (HT 58 > HT 117 > HT 130 > B cells) when they were exposed to monoclonal antibodies (mAb) to cartilage proteoglycans. Anti-proteoglycan antibodies used in this study recognize complex epitopes of core protein segment associated with carbohydrate, shared by human cartilage proteoglycans and certain lymphoma cells. The binding of these antibodies was independent of cell-cycle phase. The results suggest that the anti-proteoglycan mAbs could be used as new phenotypic markers to individualize non-Hodgkin lymphomas.

UR - http://www.scopus.com/inward/record.url?scp=0025674622&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025674622&partnerID=8YFLogxK

U2 - 10.1007/BF01754211

DO - 10.1007/BF01754211

M3 - Article

C2 - 2289206

AN - SCOPUS:0025674622

VL - 32

SP - 137

EP - 142

JO - Cancer Immunology, Immunotherapy

JF - Cancer Immunology, Immunotherapy

SN - 0340-7004

IS - 2

ER -